8-K: ReShape Lifesciences Reports Q3 2024 Results, Announces Merger and Asset Sale

ReShape Lifesciences announced its third quarter 2024 financial results, highlighting revenue growth and a strategic merger and asset sale.

Summary

• ReShape Lifesciences reported a 6.4% increase in revenue for the third quarter of 2024 compared to the same period in 2023, reaching $2.3 million.
• Revenue also increased by 16.6% compared to the second quarter of 2024, marking the third consecutive quarter of growth.
• However, year-to-date revenue for the first nine months of 2024 decreased by 7.4% to $6.2 million compared to $6.7 million in 2023.
• The company significantly reduced operating expenses by 40.6% in the first nine months of 2024 compared to the same period in 2023.
• Gross profit margin improved to 62.8% in Q3 2024, up from 59.8% in Q3 2023.
• ReShape entered into a merger agreement with Vyome Therapeutics and an asset purchase agreement with Biorad Medisys.
• The asset sale to Biorad includes the Lap-Band System, Obalon Gastric Balloon System, and the Diabetes Bloc-Stim Neuromodulation (DBSN) System for $5.16 million in cash.
• Existing ReShape stockholders will own approximately 11.1% of the combined company after the merger with Vyome, subject to adjustments based on net cash at closing.
• The company received a $241,000 supplementary grant from the NIH for the development of next-generation electrodes for its DBSN device.
• Health Canada approved the next-generation Lap-Band 2.0 FLEX.
• A 1-for-58 reverse stock split was completed in September 2024.

Sentiment

Score: 5

Explanation: The document presents a mixed picture with positive revenue growth in Q3 but a year-to-date revenue decline and a strategic shift through a merger and asset sale. The sentiment is neutral to slightly negative due to the financial challenges and the significant changes in the company's structure.

Positives

• Revenue increased for the third consecutive quarter, showing a positive trend.
• The company achieved a significant reduction in operating expenses.
• Gross profit margin improved, indicating better cost management.
• The merger with Vyome and asset sale to Biorad are expected to maximize value for shareholders.
• The company received a supplementary grant from the NIH, supporting the development of its DBSN device.
• Health Canada approval for the Lap-Band 2.0 FLEX is a positive regulatory milestone.

Negatives

• Year-to-date revenue decreased by 7.4% compared to the same period in 2023.
• The company experienced a decrease in sales volume due to competition from GLP-1 pharmaceutical weight-loss alternatives.
• Existing ReShape stockholders will own only approximately 11.1% of the combined company after the merger with Vyome.

Risks

• The company faces continued pressure from the marketing and adoption of GLP-1 pharmaceutical weight-loss alternatives.
• The merger and asset sale are subject to various conditions and may involve unexpected costs, liabilities, or delays.
• There is a risk that the merger and asset sale may not be completed.
• The company's business may suffer due to uncertainty surrounding the merger and asset sale.
• The company may face legal proceedings related to the merger or asset sale.

Future Outlook

The company anticipates significant shareholder value and growth potential from the merger with Vyome and the asset sale to Biorad. The company is focused on the newly combined entity and its future prospects.

Management Comments

• Paul F. Hickey, President and Chief Executive Officer, stated that revenues continued to rebound, increasing 16.6% over the second quarter, and that the company continued to execute on its 2024 cost reduction plan, leading to approximately 41% lower operating expenses for the first nine months of the year.
• Paul F. Hickey also noted that the company received Health Canada approval for the next generation Lap-Band 2.0 FLEX and a $241,000 supplementary grant from the NIH for its DBSN device.
• Management believes the merger with Vyome will unlock significant value for shareholders in the newly combined entity.
• Management is grateful to Series C preferred stockholders for lowering their liquidation preference, allowing common stockholders to benefit from the merger's potential.

Industry Context

The company is operating in a competitive weight loss market, facing pressure from the increasing popularity of GLP-1 pharmaceutical weight-loss alternatives. The strategic merger and asset sale are aimed at maximizing shareholder value in this challenging environment.

Comparison to Industry Standards

• ReShape's revenue growth of 16.6% in Q3 2024 compared to Q2 2024 is a positive sign, but the year-to-date revenue decline of 7.4% indicates challenges in the competitive weight loss market.
• The company's significant reduction in operating expenses by 40.6% in the first nine months of 2024 is a notable achievement, suggesting improved cost management.
• The gross profit margin of 62.8% in Q3 2024 is a positive indicator of profitability, but it is important to compare this to other medical device companies in the weight loss sector.
• The merger with Vyome and asset sale to Biorad are strategic moves to consolidate and focus on core assets, which is a common strategy in the medical device industry when facing financial challenges.
• Companies like Apollo Endosurgery and EnteroMedics (now ReShape Lifesciences) have faced similar challenges in the past with weight loss devices, highlighting the competitive nature of the market and the need for strategic shifts.

Stakeholder Impact

• Shareholders will experience a significant change in ownership structure due to the merger, with existing ReShape stockholders owning approximately 11.1% of the combined company.
• Employees may be affected by the merger and asset sale, with potential changes in roles and responsibilities.
• Customers may experience changes in product offerings and services as a result of the asset sale.
• Suppliers may need to adjust to new relationships and contracts with the acquiring companies.
• Creditors will be impacted by the assumption of liabilities by Biorad.

Next Steps

• ReShape plans to file a joint proxy statement/prospectus with the SEC in connection with the proposed Merger and Asset Sale.
• The company will seek stockholder approval for the proposed Merger and Asset Sale.
• The company will work to close the merger with Vyome and the asset sale to Biorad.
• Management will continue to focus on the newly combined entity and its future prospects.

Key Dates

Keywords

ReShape Lifesciences, Merger, Asset Sale, Vyome Therapeutics, Biorad Medisys, Lap-Band, Obalon, DBSN, Weight Loss, Metabolic Health, Financial Results, Reverse Stock Split